Gilead loses monopoly control of its blockbuster hepatitis C medicine in China | Médecins Sans Frontières Access Campaign
A Drug is 90 Percent Effective at Preventing HIV.… | Arnold Ventures
Gilead Revenue Soars on Hepatitis C Drug - The New York Times
Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back | Fierce Pharma
Gilead launches combination HIV pill in UK and Germany - PMLiVE
Federal government sues Gilead Sciences, alleging patent infringement on HIV drugs
Gilead Advancing Access®: What to Know | Prism Health North Texas
Gilead prices remdesivir at $2,340 per patient for developed countries
Gilead reports reduced mortality risk with remdesivir for Covid-19
The drug company that shocked the world with its prices dodged $10 billion in taxes, report says - The Washington Post
Top Research Reports for JPMorgan, Gilead Sciences & CSX
Untangling the Trump administration's lawsuit over an HIV prevention drug | Science | AAAS
Trump administration sues Gilead over HIV drugs
Gilead reports 3% revenue growth in Q1 2022
Gilead says generic Truvada will be available in 2020
Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut
United States v. Gilead: The Fight for PrEP | Bill of Health
New Twist in the Gilead Patent Lawsuit Over Truvada and Descovy to Prevent HIV - POZ
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine - Los Angeles Times
More evidence remdesivir helps some coronavirus patients | CNN
Gilead bags EU approval for next-generation HIV drug - PMLiVE
Gilead to launch generic versions of hepatitis C drugs | Modern Healthcare
Gilead's Truvada faces Teva generics assault amid Descovy switching campaign | Fierce Pharma
COVID-19 Drug Remdesivir Priced At More Than $3,100 Per Patient : Shots - Health News : NPR
Pharma giant Gilead sued for 'withholding' safer HIV drug | PinkNews
